Summary
Beigene, Ltd. (ONC) announced a significant regulatory milestone on January 13, 2021, with the China National Medical Products Administration (NMPA) approving its anti-PD-1 antibody, tislelizumab. This approval is for the first-line treatment of advanced squamous non-small cell lung cancer (NSCLC) when used in combination with two specific chemotherapy regimens. This marks the third NMPA approval for tislelizumab and, notably, its first approval within a lung cancer indication. This development is a key positive step for Beigene, expanding the therapeutic applications and market potential of its lead oncology asset in a major global market. Investors should view this as a crucial de-risking event and a catalyst for potential future growth, especially given the prevalence of NSCLC.
Key Highlights
- 1Tislelizumab receives NMPA approval in China for first-line advanced squamous NSCLC.
- 2The approval is for a combination therapy with two chemotherapy regimens.
- 3This is the third overall approval for tislelizumab in China.
- 4This marks the first approval of tislelizumab in a lung cancer indication.
- 5The filing includes the full press release detailing the approval as an exhibit.